Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent chemotherapy plus high-dose palliative radiotherapy versus high-dose palliative radiotherapy alone for inoperable non-small cell lung cancer
ACTRN12612001211853Phase 3Active, not recruiting
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin and vinorelbine in non-small cell lung cancer (NSCLC), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoints: Change from baseline in Intrathoracic Symptom Burden Index at 6 weeks after treatment and Change from baseline in component thoracic symptoms at 6 weeks after treatment. Started Dec 2012; status: active, not recruiting.
02
Drugs
cisplatinvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12612001211853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001211853.